title: More on aprepitant for erlotinib-induced pruritus.
authors.forename: Peter Arne
authors.initials: PA
authors.lastname: Gerber
authors.forename: Bettina Alexandra
authors.initials: BA
authors.lastname: Buhren
authors.forename: Bernhard
authors.initials: B
authors.lastname: Homey
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use; D000077608:Aprepitant; D000069347:Erlotinib Hydrochloride; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists; D056687:Off-Label Use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects*; D013373:Substance P / Q000378:metabolism
chemical_list: D000932:Antiemetics; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077608:Aprepitant; D013373:Substance P; D000069347:Erlotinib Hydrochloride